CYP2C9 and OATP1B1 Genetic Polymorphisms Affect the Metabolism and Transport of Glimepiride and Gliclazide

Overview

Journal Sci Rep

Specialty Science

Date 2018 Jul 22

PMID 30030468

Citations 10

Authors

Fayou Yang

Xiaomin Xiong

Yonghua Liu

Hong Zhang

Shibo Huang

Yuqing Xiong

Xiao Hu

Chunhua Xia

Affiliations

Soon will be listed here.

Abstract

The therapeutic use of glimepiride and gliclazide shows substantial inter-individual variation in pharmacokinetics and pharmacodynamics in human populations, which might be caused by genetic differences among individuals. The aim of this study was to assess the effect of CYP2C9 and OATP1B1 genetic polymorphisms on the metabolism and transport of glimepiride and gliclazide. The uptake of glimepiride and gliclazide was measured in OATP1B1*1a, *5 and *15-HEK293T cells, and their metabolism was measured using CYP2C9*1, *2 and *3 recombinase by LC-MS. Glimepiride in OATP1B1*1a, *5 and *15-HEK293T cells had V values of 155 ± 18.7, 80 ± 9.6, and 84.5 ± 8.2 pmol/min/mg, while gliclazide had V values of 15.7 ± 4.6, 7.2 ± 2.5, and 8.7 ± 2.4 pmol/min/mg, respectively. The clearance of glimepiride and gliclazide in OATP1B1*5 and *15 was significantly reduced compared to the wild-type. Glimepiride in the presence of CYP2C9*1, *2 and *3 recombinase had V values of 21.58 ± 7.78, 15.69 ± 5.59, and 9.17 ± 3.03 nmol/min/mg protein, while gliclazide had V values of 15.73 ± 3.11, 10.53 ± 4.06, and 6.21 ± 2.94 nmol/min/mg protein, respectively. The clearance of glimepiride and gliclazide in CYP2C9*2 and *3 was significantly reduced compared to the wild-type. These findings collectively indicate that OATP1B1*5 and *15 and CYP2C9*2 and *3 have a significant effect on the transport and metabolism of glimepiride and gliclazide.

Citing Articles

Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.

Park H, Lee S, Kang P, Cho C, Jang C, Lee S Arch Pharm Res. 2025; .

PMID: 39760829 DOI: 10.1007/s12272-024-01528-8.

Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.

Kang P, Cho C, Jang C, Lee S, Lee Y, Choi C Arch Pharm Res. 2023; 46(5):438-447.

PMID: 37097441 DOI: 10.1007/s12272-023-01448-z.

Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682.

Dawed A, Yee S, Zhou K, van Leeuwen N, Zhang Y, Siddiqui M Diabetes Care. 2022; 45(4):e82-e83.

PMID: 35349657 PMC: 9016729. DOI: 10.2337/dci21-0066.

Integration of Clinical and Scientific Principles in the Teaching of Drug-Drug Interactions.

Kim R, Morningstar-Kywi N, Haworth I Med Sci Educ. 2021; 31(6):2169-2176.

PMID: 34956730 PMC: 8651912. DOI: 10.1007/s40670-021-01395-8.

OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma.

Wen J, Zhao M Dis Markers. 2021; 2021:9711179.

PMID: 34721737 PMC: 8550862. DOI: 10.1155/2021/9711179.

References

Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M . SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2007; 82(5):541-7. DOI: 10.1038/sj.clpt.6100190. View

Zhang W, He Y, Han C, Liu Z, Li Q, Fan L . Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol. 2006; 62(5):567-72. PMC: 1885174. DOI: 10.1111/j.1365-2125.2006.02686.x. View

Zhang W, He Y, Gan Z, Fan L, Li Q, Wang A . OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin Exp Pharmacol Physiol. 2007; 34(12):1240-4. DOI: 10.1111/j.1440-1681.2007.04798.x. View

Holstein A, Beil W, Kovacs P . CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 2012; 8(12):1549-63. DOI: 10.1517/17425255.2012.722619. View

Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D . Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005; 33(6):749-53. DOI: 10.1124/dmd.105.003616. View

Lee H, Ho R . Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol. 2016; 83(6):1176-1184. PMC: 5427225. DOI: 10.1111/bcp.13207. View

Ramsey L, Bruun G, Yang W, Trevino L, Vattathil S, Scheet P . Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2011; 22(1):1-8. PMC: 3246196. DOI: 10.1101/gr.129668.111. View

Kalliokoski A, Neuvonen M, Neuvonen P, Niemi M . Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol. 2008; 48(3):311-21. DOI: 10.1177/0091270007311569. View

Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T . Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73(6):554-65. DOI: 10.1016/S0009-9236(03)00060-2. View

10.

He J, Qiu Z, Li N, Yu Y, Lu Y, Han D . Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol. 2011; 67(7):701-7. DOI: 10.1007/s00228-011-0994-7. View

11.

Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y . Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002; 302(2):804-13. DOI: 10.1124/jpet.302.2.804. View

12.

Holmboe E . Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. JAMA. 2002; 287(3):373-6. DOI: 10.1001/jama.287.3.373. View

13.

Caraco Y, Blotnick S, Muszkat M . CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2007; 83(3):460-70. DOI: 10.1038/sj.clpt.6100316. View

14.

Pirmohamed M, Park B . Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003; 192(1):23-32. DOI: 10.1016/s0300-483x(03)00247-6. View

15.

Romaine S, Bailey K, Hall A, Balmforth A . The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 2009; 10(1):1-11. DOI: 10.1038/tpj.2009.54. View

16.

Niemi M . Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2008; 8(7):787-802. DOI: 10.2217/14622416.8.7.787. View

17.

Lee C, Pieper J, Hinderliter A, Blaisdell J, Goldstein J . Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin Pharmacol Ther. 2002; 72(5):562-71. DOI: 10.1067/mcp.2002.127913. View

18.

Suga T, Yamaguchi H, Sato T, Maekawa M, Goto J, Mano N . Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3. PLoS One. 2017; 12(1):e0169719. PMC: 5218478. DOI: 10.1371/journal.pone.0169719. View

19.

Gao C, Pu Z, He C, Liang D, Jia Y, Yuan X . Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen. Oncol Rep. 2017; 38(2):1124-1132. DOI: 10.3892/or.2017.5727. View

20.

Van der Deure W, Friesema E, de Jong F, de Rijke Y, de Jong F, Uitterlinden A . Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology. 2008; 149(9):4695-701. DOI: 10.1210/en.2008-0169. View